U.S. markets closed
  • S&P 500

    3,678.43
    +92.81 (+2.59%)
     
  • Dow 30

    29,490.89
    +765.38 (+2.66%)
     
  • Nasdaq

    10,815.43
    +239.82 (+2.27%)
     
  • Russell 2000

    1,708.87
    +44.15 (+2.65%)
     
  • Crude Oil

    83.34
    +3.85 (+4.84%)
     
  • Gold

    1,708.60
    +36.60 (+2.19%)
     
  • Silver

    20.76
    +1.72 (+9.04%)
     
  • EUR/USD

    0.9826
    +0.0025 (+0.26%)
     
  • 10-Yr Bond

    3.6510
    -0.1530 (-4.02%)
     
  • GBP/USD

    1.1320
    +0.0154 (+1.38%)
     
  • USD/JPY

    144.5600
    -0.1690 (-0.12%)
     
  • BTC-USD

    19,573.30
    +402.96 (+2.10%)
     
  • CMC Crypto 200

    444.05
    +8.70 (+2.00%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Why Axsome Therapeutics Stock Is Crushing It Today

·2 min read
Why Axsome Therapeutics Stock Is Crushing It Today

The stock price of the specialist in central nervous system disorders is shooting higher today in response to the Food and Drug Administration's (FDA) approval of its major depressive disorder (MDD) drug Auvelity. Auvelity has been under review with the FDA for well over a year at this point. The drug's review took longer than expected due to issues with the analytical methods in the Chemistry, Manufacturing, and Controls section of its regulatory application.